Affordable Access

deepdyve-link
Publisher Website

An update on the safety and efficacy of regorafenib in the treatment of solid cancers.

Authors
  • Chan, Stephen L
  • Ma, Brigette By
Type
Published Article
Journal
Expert Opinion on Drug Metabolism & Toxicology
Publisher
Informa UK (Taylor & Francis)
Publication Date
Nov 01, 2014
Volume
10
Issue
11
Pages
1607–1614
Identifiers
DOI: 10.1517/17425255.2014.970169
PMID: 25316322
Source
Medline
Keywords
License
Unknown

Abstract

Regorafenib has expanded the treatment options of patients with treatment-refractory gastrointestinal stromal tumor (GIST) and metastatic colorectal cancer (CRC). Ongoing studies are now investigating the activity of regorafenib as earlier line of therapy in CRC as monotherapy or in combination with chemotherapy. In the next 5 years, the activity of regorafenib will be further defined in other cancers such as renal cell cancer (RCC), hepato-biliary and upper GI cancers. In terms of safety, clinical trials suggest that the incidence and severity of toxicities may be higher in certain populations such as those with RCC or GIST. However, most of the common toxicities of regorafenib could be managed with dose modification without resorting to permanent drug discontinuation. Education of both patients and clinicians is thus important in minimizing treatment-related toxicities and improving drug compliance.

Report this publication

Statistics

Seen <100 times